US20020144757A1 - Stainless steel alloy with improved radiopaque characteristics - Google Patents

Stainless steel alloy with improved radiopaque characteristics Download PDF

Info

Publication number
US20020144757A1
US20020144757A1 US10/103,411 US10341102A US2002144757A1 US 20020144757 A1 US20020144757 A1 US 20020144757A1 US 10341102 A US10341102 A US 10341102A US 2002144757 A1 US2002144757 A1 US 2002144757A1
Authority
US
United States
Prior art keywords
alloy
stainless steel
steel alloy
series
austenitic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/103,411
Inventor
Charles Craig
Herbert Radisch
Thomas Trozera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Scimed Life Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems Inc filed Critical Scimed Life Systems Inc
Priority to US10/103,411 priority Critical patent/US20020144757A1/en
Assigned to SCIMED LIFE SYSTEMS, INC. reassignment SCIMED LIFE SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRAIG, CHARLES HORACE, RADISCH, HERBERT R., JR., TROZERA, THOMAS
Publication of US20020144757A1 publication Critical patent/US20020144757A1/en
Assigned to BOSTON SCIENTIFIC SCIMED, INC. reassignment BOSTON SCIENTIFIC SCIMED, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCIMED LIFE SYSTEMS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C38/00Ferrous alloys, e.g. steel alloys
    • C22C38/18Ferrous alloys, e.g. steel alloys containing chromium
    • C22C38/40Ferrous alloys, e.g. steel alloys containing chromium with nickel
    • C22C38/44Ferrous alloys, e.g. steel alloys containing chromium with nickel with molybdenum or tungsten
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C38/00Ferrous alloys, e.g. steel alloys
    • C22C38/002Ferrous alloys, e.g. steel alloys containing In, Mg, or other elements not provided for in one single group C22C38/001 - C22C38/60
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C38/00Ferrous alloys, e.g. steel alloys
    • C22C38/18Ferrous alloys, e.g. steel alloys containing chromium
    • C22C38/40Ferrous alloys, e.g. steel alloys containing chromium with nickel
    • C22C38/58Ferrous alloys, e.g. steel alloys containing chromium with nickel with more than 1.5% by weight of manganese

Definitions

  • This invention relates to an austenitic steel alloy, and in particular to such an alloy and an article made therefrom in which the elements are closely controlled to provide a unique combination of high tensile strength, ductility, good resistance to stress cracking and corrosion, and have improved radiopaque characteristics.
  • Austenite generally does not exist at room temperature in plain-carbon and low-alloy steels, other than as small amounts of retained austenite that did not transform during rapid cooling.
  • austenite is the dominant microstructure.
  • sufficient quantities of alloying elements that stabilize austenite at room temperature are present (e.g., manganese and nickel).
  • the crystal structure of austenite is face-centered cubic (fcc) as compared to ferrite, which has a body centered cubic (bcc) lattice.
  • An fcc alloy has certain desirable characteristics; for example, it has low-temperature toughness, excellent weldability, and is nonmagnetic. Because of their high alloy content, austenitic steels are usually corrosion resistant. Disadvantages of the austenitic steels are their relative high costs, their susceptibility to stress-corrosion cracking (certain austenitic steels), the fact that they cannot be strengthened other than by cold working, and interstitial solid-solution strengthening.
  • the austenitic stainless steels (e.g., type 301, 302, 303, 304, 305, 308, 309, 310, 314, 316, 317, 321, 330, 347, 348, and 384) generally contain from 6 to 22% nickel to stabilize the austenite microstructure at room temperature. They also contain other alloying elements, such as chromium (16 to 26%) for corrosion resistance, and smaller amounts of manganese and molybdenum.
  • the widely used type 304 stainless steel contains 18 to 20% Cr and 8 to 10.5% Ni, and is also called 18-8 stainless steel.
  • the yield strength of annealed type 304 stainless steel is typically 290 MPa (40 ksi), with a tensile strength of about 580 MPa (84 ksi).
  • both yield and tensile strength can be substantially increased by cold working.
  • the increase in strength is offset by a substantial decrease in ductility, for example, from about 55% elongation in the annealed condition to about 25% elongation after cold working.
  • Some austenitic stainless steels (type 200, 201, 202, and 205) employ interstitial solid-solution strengthening with nitrogen addition.
  • Austenite like ferrite, can be strengthened by interstitial elements such as carbon and nitrogen.
  • carbon is usually excluded because of the deleterious effect associated with precipitation of chromium carbides on austenite grain boundaries (a process called sensitization).
  • These chromium carbides deplete the grain-boundary regions of chromium, and the denuded boundaries are extremely susceptible to corrosion.
  • Such steels can be desensitized by heating to high temperature to dissolve the carbides and place the chromium back into solution in the austenite. Nitrogen, on the other hand, is soluble in austenite and is added for strengthening.
  • type 201 stainless steel has composition ranges of 5.5 to 7.5% Mn, 16 to 18% Cr, 3.5 to 5.5% Ni, and 0.25% N.
  • the other type 2xx series of steels contain from 0.25 to 0.40% N.
  • austenitic manganese steel Another important austenitic steel is austenitic manganese steel. Developed by Sir Robert Hadfield in the late 1890s, these steels remain austenitic after water quenching and have considerable strength and toughness. A typical Hadfield manganese steel contains 10 to 14% Mn, 0.95 to 1.4% C, and 0.3 to 1% Si. Solution annealing is necessary to suppress the formation of iron carbides. The carbon must be in solid solution to stabilize the austenite. When completely austenitic, these steels can be work hardened to provide higher hardness and wear resistance. A work-hardened Hadfield manganese steel has excellent resistance to abrasive wear under heavy loading. Because of this characteristic, these steels are ideal forjaw crushers and other crushing and grinding components in the mining industry. Also, Hadfield manganese steels have long been used for railway frogs (components used at the junction point of two railroad lines).
  • AISI Types 304L, 316L, 321 and 347 stainless steels are austenitic, chromium-nickel and chromium-nickel-molybdenum stainless steels having the following compositions in weight percent: Type 304 L Type 316 L Type 321 Type 347 wt. % wt. % wt. % wt. % wt.
  • chromium-nickel and chromium-nickel-molybdenum stainless steels are known to be useful for applications which require good non-magnetic behavior, in combination with good corrosion resistance.
  • One disadvantage of the series 300 stainless steels is their poor radiopacity.
  • a stent made from standard 300 series stainless steel can not be sufficiently radiopaque for clinical observation due to the thin cross-section of the struts. Therefore, this present invention alloy can be useful in clinical observations because it can be radiopaque in these cross-sections.
  • chromium-nickel and chromium-nickel-molybdenum stainless steels particularly for these alloys having increased radiopaque characteristics.
  • the invention generally relates to an austenitic 300 series stainless steel alloy that provides better radiopacity than is provided by the known austenitic stainless steels.
  • One application for the present invention is to use the austenitic stainless steel alloy with increased radiopacity for fabricating intravascular stents.
  • the interventionalist uses angiographic and fluoroscopic techniques that employ X-rays and materials that are radiopaque to the X-rays to visualize the location or placement of the particular device within the human vasculature.
  • stents are fabricated from a variety of stainless steels, with the 316 series representing a large percentage of the stainless steel used to fabricate currently marketed stents.
  • the typical composition of 316 series stainless steel is shown in Table I. TABLE I Component (%) C Mn Si P S Cr Mo Ni Fe Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774
  • Modified stainless steel of the 300 series for increasing radiopaque characteristic could be produced by creating alloys containing varying amounts of elements that have dense mass and radiopaque characteristics.
  • the chemical make-up of standard series 300 stainless steel, using series 316 as an example, along with the possible chemical ranges of various such alloys are shown on the following Table. TABLE II Component (%) C Mn Si P S Cr Mo Ni Fe X Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
  • Modified 300A ⁇ 0.030 ⁇ 2.000 ⁇ 0.750 ⁇ 0.023 ⁇ 0.010 12.000- 000- 10.000- 46.185- 2.000- 20.000 3.000 18.000 74.000 10.000
  • Another object of the present invention is to provide a material which has superior properties, including radiopacity, for fabricating any stent design or format.
  • the alloy according to the present invention comprises a stainless steel series 300 compound used to fabricate a stent which replaces a portion of the iron or molybdenum component of the 300 series with one or combination of several elements containing radiopaque properties.
  • elements are gold (Au), osmium (Os), palladium (Pd), platinum (Pt), rhenium (Re), tantalum (Ta), tungsten (W) or iridium (Ir).
  • This group consists of elements with dense masses. The dense mass provides these materials with improved absorption of X-rays thus providing improved radiopaque characteristics.
  • X-rays employed in angiogram procedures or cineograms allow the visualization of certain devices, such as a stent, during all phases of a standard clinical procedure.
  • the alloy for fabricating stents contains a range of 2.0 to 10.0 percent of one or more of these radiopaque elements, with a preferred range of 4.0 to 5.0 percent. Replacing too much of the radiopaque element with the iron or molybdenum component could possible decrease the beneficial qualities of 300 series stainless steel for manufacturing stents without contributing significantly improved radiopaque characteristics. It is anticipated that various combinations of the radiopaque elements can be used to replace the iron or molybdenum component without adversely affecting the ability to form austenite.
  • the alloy for fabricating a series 300 stainless steel with improved radiopaque properties can contain up to 0.03% of carbon.
  • the carbon element contributes to good hardness capability and high tensile strength by combining with other elements such as chromium and molybdenum to form carbides during heat treatment. However, too much carbon adversely affects the fracture toughness of this alloy.
  • Chromium contributes to the good hardenability corrosion resistance and hardness capability of this alloy and benefits the desired low ductile-brittle transition temperature of the alloy. Therefore, at least about 12%, and preferably at least about 17.5% chromium is present. Above about 20% chromium the alloy is susceptible to rapid overaging such that the unique combination of high tensile strength and high fracture toughness is not attainable.
  • Nickel contributes to the hardenability of this alloy such that the alloy can be hardened with or without rapid quenching techniques. Nickel benefits the fracture toughness and stress corrosion cracking resistance provided by this alloy and contributes to the desired low ductile-to-brittle transition temperature. Accordingly, at least about 10.0%, and preferably at least about 14.7% nickel is present. Above about 18% nickel, the fracture toughness and impact toughness of the alloy can be adversely affected because the solubility of carbon in the alloy is reduced which may result in carbide precipitation in the grain boundaries when the alloy is cooled at a slow rate, such as when air cooled following forging.
  • Molybdenum is present in this alloy because it benefits the desired low ductile brittle transition temperature of the alloy. Above about 3% molybdenum the fracture toughness of the alloy is adversely affected. Preferably, molybdenum is limited to not more than about 1.2%. However, the entire portion of the molybdenum can be replaced with certain radiopaque elements such as Ta without adversely affecting the desired characteristics of the alloy.
  • the alloy for fabricating a series 300 stainless steel stent with radiopaque properties can also contain up to 2.0% manganese.
  • Manganese is partly depended upon to maintain the austenitic, nonmagnetic character of the alloy. Manganese also plays a role, in part, providing resistance to corrosive attack.
  • the balance of the alloy according to the present invention is essentially iron except for the usual impurities found in commercial grades of alloys intended for similar service or use.
  • the levels of such elements must be controlled so as not to adversely affect the desired properties of this alloy.
  • phosphorus is limited to not more than about 0.008% and sulfur is limited to not more 0.004%.
  • the alloy for fabricating a series 300 stainless steel alloy with radiopaque properties can contain up to 0.75% silicon.
  • the alloy for fabricating a series 300 stainless steel stent with radiopaque properties can contain up to 0.023% and 0.002% phosphorus and sulfur, respectively, without affecting the desirable properties.
  • the alloy of the present invention can be formed into a variety of shapes for a wide variety of uses and lends itself to the formation of billets, bars, rod, wire, strip, plate, or sheet using conventional practices.
  • the alloy according to the present invention can be useful in a variety of applications requiring high strength and radiopaque characteristics, for example, to fabricate stents of other medical applications.
  • the alloy according to the present invention provides a unique combination of tensile strength and radiopaque characteristics not provided by known series 300 stainless steel alloys. This alloy is well suited to applications where high strength, biocompatibility and radiopacity are required.
  • the alloy of the present invention is readily melted using conventional and/or vacuum melting techniques. For best results, as when additional refining is desired, a multiple melting practice is preferred. The preferred practice is to melt a heat in a vacuum induction furnace (VIM) and cast the heat in the form of an electrode. The electrode is then remelted in a vacuum arc furnace (VAR) and recast into one or more ingots.
  • VIP vacuum induction furnace
  • VAR vacuum arc furnace
  • the alloy can be prepared from heats which can be melted under argon cover and cast as ingots.
  • the ingots can be maintained at a temperature range of 2100-2300 degree F. (1149-1260 degree C.) for 2 hours and then pressed into billets.
  • the billets may be ground to remove surface defects and the ends cut off.
  • the billets can then be hot rolled to form intermediate bars with an intermediate diameter.
  • the intermediate bars are hot rolled to a diameter of 0.7187 in. (1.82 cm) from a temperature range of 2100-2300.degree. F. (1 149-1260.degree. C.).
  • the round bars are straightened and then turned to a final diameter or alternately, sheets are rolled to the desired diameter with optional intermediate anneals are required. All of the bars or sheets can be pointed, solution annealed, water quenched, and acid cleaned to remove surface scale.
  • stents can be fabricated from the present invention alloy and testing in animal studies utilizing standard angiography equipment.
  • the stent fabricated from the alloy can be deployed in an animal model with other FDA approved stents with know radiopacity characteristics.

Abstract

The present invention is directed towards an austenitic, stainless steel series 300 alloy having improved radiopaque characteristics. The modified stainless steel alloy consists essentially of, in weight percent, about C Mn Si P S ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 Cr Mo Ni Fe “X” 12.000- 0.00- 10.000- 46.185- 2.000- 20.000 3.000 18.000 74.000 10.000
whereby variable “X” could be comprised from a group consisting of Gold, Osmium, Palladium, Platinum, Rhenium, Tantalum, Tungsten or Iridium. The alloy provides a unique combination of strength, ductility, corrosion resistance, and other mechanical properties which also has improved radiopaque characteristics.

Description

    PRIOR APPLICATIONS
  • This application is a continuation-in-part of application Ser. No. 09/612,157 filed on Jul. 7, 2000. It was disclosed in the application that this inventions is an austenitic steel alloy having radiopaque characteristics.[0001]
  • BACKGROUND OF THE INVENTION
  • This invention relates to an austenitic steel alloy, and in particular to such an alloy and an article made therefrom in which the elements are closely controlled to provide a unique combination of high tensile strength, ductility, good resistance to stress cracking and corrosion, and have improved radiopaque characteristics. [0002]
  • Austenite generally does not exist at room temperature in plain-carbon and low-alloy steels, other than as small amounts of retained austenite that did not transform during rapid cooling. However, in certain high-alloy steels, such as the austenitic stainless steels and Hadfield austenitic manganese steel, austenite is the dominant microstructure. In these steels, sufficient quantities of alloying elements that stabilize austenite at room temperature are present (e.g., manganese and nickel). The crystal structure of austenite is face-centered cubic (fcc) as compared to ferrite, which has a body centered cubic (bcc) lattice. An fcc alloy has certain desirable characteristics; for example, it has low-temperature toughness, excellent weldability, and is nonmagnetic. Because of their high alloy content, austenitic steels are usually corrosion resistant. Disadvantages of the austenitic steels are their relative high costs, their susceptibility to stress-corrosion cracking (certain austenitic steels), the fact that they cannot be strengthened other than by cold working, and interstitial solid-solution strengthening. [0003]
  • The austenitic stainless steels (e.g., type 301, 302, 303, 304, 305, 308, 309, 310, 314, 316, 317, 321, 330, 347, 348, and 384) generally contain from 6 to 22% nickel to stabilize the austenite microstructure at room temperature. They also contain other alloying elements, such as chromium (16 to 26%) for corrosion resistance, and smaller amounts of manganese and molybdenum. The widely used type 304 stainless steel contains 18 to 20% Cr and 8 to 10.5% Ni, and is also called 18-8 stainless steel. The yield strength of annealed type 304 stainless steel is typically 290 MPa (40 ksi), with a tensile strength of about 580 MPa (84 ksi). However, both yield and tensile strength can be substantially increased by cold working. However, the increase in strength is offset by a substantial decrease in ductility, for example, from about 55% elongation in the annealed condition to about 25% elongation after cold working. [0004]
  • Some austenitic stainless steels (type 200, 201, 202, and 205) employ interstitial solid-solution strengthening with nitrogen addition. Austenite, like ferrite, can be strengthened by interstitial elements such as carbon and nitrogen. However, carbon is usually excluded because of the deleterious effect associated with precipitation of chromium carbides on austenite grain boundaries (a process called sensitization). These chromium carbides deplete the grain-boundary regions of chromium, and the denuded boundaries are extremely susceptible to corrosion. Such steels can be desensitized by heating to high temperature to dissolve the carbides and place the chromium back into solution in the austenite. Nitrogen, on the other hand, is soluble in austenite and is added for strengthening. To prevent nitrogen from forming deleterious nitrides, manganese is added to lower the activity of nitrogen in the austenite, as well as to stabilize the austenite. For example, type 201 stainless steel has composition ranges of 5.5 to 7.5% Mn, 16 to 18% Cr, 3.5 to 5.5% Ni, and 0.25% N. The other type 2xx series of steels contain from 0.25 to 0.40% N. [0005]
  • Another important austenitic steel is austenitic manganese steel. Developed by Sir Robert Hadfield in the late 1890s, these steels remain austenitic after water quenching and have considerable strength and toughness. A typical Hadfield manganese steel contains 10 to 14% Mn, 0.95 to 1.4% C, and 0.3 to 1% Si. Solution annealing is necessary to suppress the formation of iron carbides. The carbon must be in solid solution to stabilize the austenite. When completely austenitic, these steels can be work hardened to provide higher hardness and wear resistance. A work-hardened Hadfield manganese steel has excellent resistance to abrasive wear under heavy loading. Because of this characteristic, these steels are ideal forjaw crushers and other crushing and grinding components in the mining industry. Also, Hadfield manganese steels have long been used for railway frogs (components used at the junction point of two railroad lines). [0006]
  • AISI Types 304L, 316L, 321 and 347 stainless steels are austenitic, chromium-nickel and chromium-nickel-molybdenum stainless steels having the following compositions in weight percent: [0007]
    Type 304 L Type 316 L Type 321 Type 347
    wt. % wt. % wt. % wt. %
    C  0.03 max  0.03 max  0.08 max  0.08 max
    Mn  2.00 max  2.00 max  2.00 max  2.00 max
    Si  1.00 max  1.00 max  1.00 max  1.00 max
    P  0.045 max  0.045 max  0.045 max  0.045 max
    S  0.03 max  0.03 max  0.03 max  0.03 max
    Cr 18.0-20.0 16.0-18.0 17.0-19.0 17.0-19.0
    Ni  8.0-12.0 10.-14.0  9.0-12.0  9.0-13.0
    N 0.10 max  0.10 max  0.10 max
    Mo  2.0-3.0
    Fe Bal. Bal. Bal. Bal.
  • The above-listed chromium-nickel and chromium-nickel-molybdenum stainless steels are known to be useful for applications which require good non-magnetic behavior, in combination with good corrosion resistance. One disadvantage of the series 300 stainless steels is their poor radiopacity. For example, a stent made from standard 300 series stainless steel can not be sufficiently radiopaque for clinical observation due to the thin cross-section of the struts. Therefore, this present invention alloy can be useful in clinical observations because it can be radiopaque in these cross-sections. There continues to be a demand for improved chromium-nickel and chromium-nickel-molybdenum stainless steels, particularly for these alloys having increased radiopaque characteristics. [0008]
  • Given the foregoing, it would be highly desirable to have an austenitic stainless steel that provides better radiopacity than is provided by the known austenitic stainless steels. [0009]
  • SUMMARY OF THE INVENTION
  • The invention generally relates to an austenitic 300 series stainless steel alloy that provides better radiopacity than is provided by the known austenitic stainless steels. One application for the present invention is to use the austenitic stainless steel alloy with increased radiopacity for fabricating intravascular stents. In this clinical setting, the interventionalist uses angiographic and fluoroscopic techniques that employ X-rays and materials that are radiopaque to the X-rays to visualize the location or placement of the particular device within the human vasculature. Typically stents are fabricated from a variety of stainless steels, with the 316 series representing a large percentage of the stainless steel used to fabricate currently marketed stents. The typical composition of 316 series stainless steel is shown in Table I. [0010]
    TABLE I
    Component (%)
    C Mn Si P S Cr Mo Ni Fe
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774
  • While the 300 series of stainless steel has several characteristics, such as strength, flexibility, fatigue resistance, biocompatibility, etc. rendering it a good material to make an intravascular stent, one significant disadvantage of 316 series stainless steel, as well as other 300 series of stainless steel, is that they have relatively low radiopaque qualities and therefore not readably visual under fluoroscopic observation. A need has arisen to modify the stainless steel composition so it has radiopaque properties while at the same time, maintaining those characteristics which render it as a material of choice for fabricating stents. [0011]
  • Modified stainless steel of the 300 series for increasing radiopaque characteristic could be produced by creating alloys containing varying amounts of elements that have dense mass and radiopaque characteristics. The chemical make-up of standard series 300 stainless steel, using series 316 as an example, along with the possible chemical ranges of various such alloys are shown on the following Table. [0012]
    TABLE II
    Component (%)
    C Mn Si P S Cr Mo Ni Fe X
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 300A ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 000- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • Other features and advantages of the present invention will become more apparent from the following detailed description of the invention. [0013]
  • It is an object of the present invention to provide an austenitic 300 series stainless steel alloy that provides better radiopacity than is provided by the known austenitic stainless steels. [0014]
  • It is another object of the present invention to provide a stent or prosthesis which can be readily delivered to, expanded and embedded into an obstruction or vessel wall with relatively high radiopaque characteristics for fluoroscopy during all phases of the interventional procedure. [0015]
  • Another object of the present invention is to provide a material which has superior properties, including radiopacity, for fabricating any stent design or format.[0016]
  • DETAILED DESCRIPTION
  • The alloy according to the present invention comprises a stainless steel series 300 compound used to fabricate a stent which replaces a portion of the iron or molybdenum component of the 300 series with one or combination of several elements containing radiopaque properties. Examples of such elements are gold (Au), osmium (Os), palladium (Pd), platinum (Pt), rhenium (Re), tantalum (Ta), tungsten (W) or iridium (Ir). This group consists of elements with dense masses. The dense mass provides these materials with improved absorption of X-rays thus providing improved radiopaque characteristics. By including one or more of these elements in a series 300 stainless steel, thereby creating the present invention alloy, X-rays employed in angiogram procedures or cineograms allow the visualization of certain devices, such as a stent, during all phases of a standard clinical procedure. The alloy for fabricating stents contains a range of 2.0 to 10.0 percent of one or more of these radiopaque elements, with a preferred range of 4.0 to 5.0 percent. Replacing too much of the radiopaque element with the iron or molybdenum component could possible decrease the beneficial qualities of 300 series stainless steel for manufacturing stents without contributing significantly improved radiopaque characteristics. It is anticipated that various combinations of the radiopaque elements can be used to replace the iron or molybdenum component without adversely affecting the ability to form austenite. [0017]
  • The foregoing, as well as additional objects and advantages of the present invention, achieved in a series 300 stainless steel alloy, is compared with standard 316 stainless steel and summarized in Tables III through XI below, containing in weight percent, about: [0018]
    TABLE III
    Component (%)
    C Mn Si P S Cr Mo Ni Fe X
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 300A ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0019]
    TABLE IV
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Au
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0020]
    TABLE V
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Os
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0021]
    TABLE VI
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Pd
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0022]
    TABLE VII
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Pt
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0023]
    TABLE VIII
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Re
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0024]
    TABLE IX
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Ta
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0025]
    TABLE X
    Component (%)
    C Mn Si P S Cr Mo Ni Fe W
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • [0026]
    TABLE XI
    Component (%)
    C Mn Si P S Cr Mo Ni Fe Ir
    Standard 316 0.020 1.760 0.470 0.014 0.002 17.490 2.790 14.680 62.774 0.000
    Modified 316B ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000-
    20.000 3.000 18.000 74.000 10.000
  • The alloy for fabricating a series 300 stainless steel with improved radiopaque properties can contain up to 0.03% of carbon. The carbon element contributes to good hardness capability and high tensile strength by combining with other elements such as chromium and molybdenum to form carbides during heat treatment. However, too much carbon adversely affects the fracture toughness of this alloy. [0027]
  • Chromium contributes to the good hardenability corrosion resistance and hardness capability of this alloy and benefits the desired low ductile-brittle transition temperature of the alloy. Therefore, at least about 12%, and preferably at least about 17.5% chromium is present. Above about 20% chromium the alloy is susceptible to rapid overaging such that the unique combination of high tensile strength and high fracture toughness is not attainable. [0028]
  • Nickel contributes to the hardenability of this alloy such that the alloy can be hardened with or without rapid quenching techniques. Nickel benefits the fracture toughness and stress corrosion cracking resistance provided by this alloy and contributes to the desired low ductile-to-brittle transition temperature. Accordingly, at least about 10.0%, and preferably at least about 14.7% nickel is present. Above about 18% nickel, the fracture toughness and impact toughness of the alloy can be adversely affected because the solubility of carbon in the alloy is reduced which may result in carbide precipitation in the grain boundaries when the alloy is cooled at a slow rate, such as when air cooled following forging. [0029]
  • Molybdenum is present in this alloy because it benefits the desired low ductile brittle transition temperature of the alloy. Above about 3% molybdenum the fracture toughness of the alloy is adversely affected. Preferably, molybdenum is limited to not more than about 1.2%. However, the entire portion of the molybdenum can be replaced with certain radiopaque elements such as Ta without adversely affecting the desired characteristics of the alloy. [0030]
  • The alloy for fabricating a series 300 stainless steel stent with radiopaque properties can also contain up to 2.0% manganese. Manganese is partly depended upon to maintain the austenitic, nonmagnetic character of the alloy. Manganese also plays a role, in part, providing resistance to corrosive attack. [0031]
  • The balance of the alloy according to the present invention is essentially iron except for the usual impurities found in commercial grades of alloys intended for similar service or use. The levels of such elements must be controlled so as not to adversely affect the desired properties of this alloy. For example, phosphorus is limited to not more than about 0.008% and sulfur is limited to not more 0.004%. In addition, the alloy for fabricating a series 300 stainless steel alloy with radiopaque properties can contain up to 0.75% silicon. Furthermore, the alloy for fabricating a series 300 stainless steel stent with radiopaque properties can contain up to 0.023% and 0.002% phosphorus and sulfur, respectively, without affecting the desirable properties. [0032]
  • No special techniques are required in melting, casting, or working the alloy of the present invention. Arc melting followed by argon-oxygen decarburization is the preferred method of melting and refining, but other practices can be used. In addition, this alloy can be made using powder metallurgy techniques, if desired. This alloy is also suitable for continuous casting techniques. [0033]
  • The alloy of the present invention can be formed into a variety of shapes for a wide variety of uses and lends itself to the formation of billets, bars, rod, wire, strip, plate, or sheet using conventional practices. [0034]
  • The alloy according to the present invention can be useful in a variety of applications requiring high strength and radiopaque characteristics, for example, to fabricate stents of other medical applications. [0035]
  • It is apparent from the foregoing description and the accompanying examples, that the alloy according to the present invention provides a unique combination of tensile strength and radiopaque characteristics not provided by known series 300 stainless steel alloys. This alloy is well suited to applications where high strength, biocompatibility and radiopacity are required. [0036]
  • The terms and expressions which have been employed herein are used as terms of description and not of limitation. There is no intention in the use of such terms and expressions to exclude any equivalents of the features described or any portions thereof. It is recognized, however, that various modifications are possible within the scope of the invention claimed. [0037]
  • While the invention has been illustrated and described herein in terms of its use as an intravascular stent, it will be apparent to those skilled in the art that the stent can be used in other instances such as to expand prostate urethras in cases of prostate hyperplasia. Other modifications and improvements may be made without departing from the scope of the invention. [0038]
  • Other modifications and improvements can be made to the invention without departing from the scope thereof. [0039]
  • The alloy of the present invention is readily melted using conventional and/or vacuum melting techniques. For best results, as when additional refining is desired, a multiple melting practice is preferred. The preferred practice is to melt a heat in a vacuum induction furnace (VIM) and cast the heat in the form of an electrode. The electrode is then remelted in a vacuum arc furnace (VAR) and recast into one or more ingots. [0040]
  • The alloy can be prepared from heats which can be melted under argon cover and cast as ingots. The ingots can be maintained at a temperature range of 2100-2300 degree F. (1149-1260 degree C.) for 2 hours and then pressed into billets. The billets may be ground to remove surface defects and the ends cut off. The billets can then be hot rolled to form intermediate bars with an intermediate diameter. The intermediate bars are hot rolled to a diameter of 0.7187 in. (1.82 cm) from a temperature range of 2100-2300.degree. F. (1 149-1260.degree. C.). The round bars are straightened and then turned to a final diameter or alternately, sheets are rolled to the desired diameter with optional intermediate anneals are required. All of the bars or sheets can be pointed, solution annealed, water quenched, and acid cleaned to remove surface scale. [0041]
  • To evaluate improved radiopacity of the present invention, stents can be fabricated from the present invention alloy and testing in animal studies utilizing standard angiography equipment. The stent fabricated from the alloy can be deployed in an animal model with other FDA approved stents with know radiopacity characteristics. [0042]
  • The terms and expressions that have been employed herein are used as terms of description and not of limitation. There is no intention in the use of such terms and expressions to exclude any equivalents of the features described or any portions thereof. It is recognized, however, that various modifications are possible within the scope of the invention claimed. [0043]

Claims (9)

We claim:
1. A modified series 300 stainless steel alloy which provides increased radiopaque characteristics over standard 300 stainless steel.
2. A steel alloy as recited in claim 1, wherein said alloy is used for fabricating intravascular stents.
3. A steel alloy as recited in claim 1, wherein said steel alloy consisting essentially of, in weight percent, about
C Mn Si P S Cr Mo Ni Fe “X” ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000- 20.000 3.000 18.000 74.000 10.000
whereby variable “x” could be comprised from a group consisting of Ir.
4. A steel alloy as recited in claim 3, wherein a portion of Iridium replaces a portion of Iron.
5. A steel alloy as recited in claim 3, wherein a portion of Iridium replaces a portion of Molybdenum.
6. A steel alloy as recited in claim 3, wherein a portion of Iridium replaces a portion of both Iron and Molybdenum.
7. A modified series 300 stainless steel alloy which provides increased radiopaque characteristics over standard 300 stainless steel, said alloy consisting essentially of, in weight percent, about
C Mn Si P S Cr Mo Ni Ir ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 2.000- 10.000- 2.000- 20.000 3.000 18.000 10.000
and the balance is essentially iron.
8. A modified series 300 stainless steel alloy which provides increased radiopaque characteristics over standard 300 stainless steel, said alloy consisting essentially of, in weight percent, about
C Mn Si P S Cr Mo Ni Ir ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 2.000- 20.000 3.000 18.000 10.000
and the balance is essentially iron.
9. A modified series 300 stainless steel alloy which provides increased radiopaque characteristics over standard 300 stainless steel, said alloy consisting essentially of, in weight percent, about
C Mn Si P S Cr Mo Ni Fe “X” ≦0.030 ≦2.000 ≦0.750 ≦0.023 ≦0.010 12.000- 0.00- 10.000- 46.185- 2.000- 20.000 3.000 18.000 74.000 10.000
whereby variable “X” could be comprised from a group consisting of Gold, Osmium, Palladium, Platinum, Rhenium, Tantalum, Tungsten or Iridium.
US10/103,411 2000-07-07 2002-03-20 Stainless steel alloy with improved radiopaque characteristics Abandoned US20020144757A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/103,411 US20020144757A1 (en) 2000-07-07 2002-03-20 Stainless steel alloy with improved radiopaque characteristics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61215700A 2000-07-07 2000-07-07
US10/103,411 US20020144757A1 (en) 2000-07-07 2002-03-20 Stainless steel alloy with improved radiopaque characteristics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US61215700A Continuation-In-Part 2000-07-07 2000-07-07

Publications (1)

Publication Number Publication Date
US20020144757A1 true US20020144757A1 (en) 2002-10-10

Family

ID=24451960

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/103,411 Abandoned US20020144757A1 (en) 2000-07-07 2002-03-20 Stainless steel alloy with improved radiopaque characteristics

Country Status (1)

Country Link
US (1) US20020144757A1 (en)

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204749A1 (en) * 2003-04-11 2004-10-14 Richard Gunderson Stent delivery system with securement and deployment accuracy
US20040267348A1 (en) * 2003-04-11 2004-12-30 Gunderson Richard C. Medical device delivery systems
US20060079953A1 (en) * 2004-10-08 2006-04-13 Gregorich Daniel J Medical devices and methods of making the same
US20060100696A1 (en) * 2004-11-10 2006-05-11 Atanasoska Ljiljana L Medical devices and methods of making the same
US20060097242A1 (en) * 2004-11-10 2006-05-11 Mitsubishi Denki Kabushiki Kaisha Semiconductor light-emitting device
US20060153729A1 (en) * 2005-01-13 2006-07-13 Stinson Jonathan S Medical devices and methods of making the same
US20060222844A1 (en) * 2005-04-04 2006-10-05 Stinson Jonathan S Medical devices including composites
US20060224231A1 (en) * 2005-03-31 2006-10-05 Gregorich Daniel J Endoprostheses
US20060229711A1 (en) * 2005-04-05 2006-10-12 Elixir Medical Corporation Degradable implantable medical devices
US20060259126A1 (en) * 2005-05-05 2006-11-16 Jason Lenz Medical devices and methods of making the same
US20060276910A1 (en) * 2005-06-01 2006-12-07 Jan Weber Endoprostheses
US20060276875A1 (en) * 2005-05-27 2006-12-07 Stinson Jonathan S Medical devices
US20070114701A1 (en) * 2005-11-18 2007-05-24 Stenzel Eric B Methods and apparatuses for manufacturing medical devices
US20080069858A1 (en) * 2006-09-20 2008-03-20 Boston Scientific Scimed, Inc. Medical devices having biodegradable polymeric regions with overlying hard, thin layers
US20080071344A1 (en) * 2006-09-18 2008-03-20 Boston Scientific Scimed, Inc. Medical device with porous surface
US20080071355A1 (en) * 2006-09-14 2008-03-20 Boston Scientific Scimed, Inc. Medical Devices with Drug-Eluting Coating
WO2008063775A2 (en) * 2006-10-13 2008-05-29 Boston Scientific Limited Medical devices including hardened alloys
US20080160259A1 (en) * 2006-12-28 2008-07-03 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20080161900A1 (en) * 2006-06-20 2008-07-03 Boston Scientific Scimed, Inc. Medical devices including composites
US20080294238A1 (en) * 2007-05-25 2008-11-27 Boston Scientific Scimed, Inc. Connector Node for Durable Stent
US20090118814A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118812A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090149942A1 (en) * 2007-07-19 2009-06-11 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US20090299468A1 (en) * 2008-05-29 2009-12-03 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090319032A1 (en) * 2008-06-18 2009-12-24 Boston Scientific Scimed, Inc Endoprosthesis coating
US20100010620A1 (en) * 2008-07-09 2010-01-14 Boston Scientific Scimed, Inc. Stent
US20100057188A1 (en) * 2008-08-28 2010-03-04 Boston Scientific Scimed, Inc. Endoprostheses with porous regions and non-polymeric coating
US20100063584A1 (en) * 2008-09-05 2010-03-11 Boston Scientific Scimed, Inc. Endoprostheses
US20100217370A1 (en) * 2009-02-20 2010-08-26 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
WO2010101988A2 (en) 2009-03-04 2010-09-10 Boston Scientific Scimed, Inc. Endoprostheses
US20100305682A1 (en) * 2006-09-21 2010-12-02 Cleveny Technologies Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
US20110022162A1 (en) * 2009-07-23 2011-01-27 Boston Scientific Scimed, Inc. Endoprostheses
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7955382B2 (en) 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
WO2011119430A1 (en) 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprosthesis
US20110238153A1 (en) * 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprostheses
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
WO2011126708A1 (en) 2010-04-06 2011-10-13 Boston Scientific Scimed, Inc. Endoprosthesis
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
WO2012142319A1 (en) 2011-04-13 2012-10-18 Micell Technologies, Inc. Stents having controlled elution
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
WO2013090145A1 (en) 2011-12-13 2013-06-20 Boston Scientific Scimed, Inc. Decalcifying heart valve
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8920490B2 (en) 2010-05-13 2014-12-30 Boston Scientific Scimed, Inc. Endoprostheses
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
CN105821343A (en) * 2016-05-24 2016-08-03 江苏金基特钢有限公司 Production method of special steel
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
CN106148852A (en) * 2015-04-02 2016-11-23 上海微创医疗器械(集团)有限公司 A kind of alloy material and implantable medical devices
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN116623105A (en) * 2023-07-24 2023-08-22 中科艾尔(北京)科技有限公司 Ultra-high purity 316L stainless steel and preparation method thereof
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2451749A (en) * 1946-05-31 1948-10-19 Kreisler Mfg Corp Jacques Bracelet or the like and method of making the same
US4244754A (en) * 1975-07-05 1981-01-13 The Foundation: The Research Institute Of Electric And Magnetic Alloys Process for producing high damping capacity alloy and product
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US4891080A (en) * 1988-06-06 1990-01-02 Carpenter Technology Corporation Workable boron-containing stainless steel alloy article, a mechanically worked article and process for making thereof
US5449373A (en) * 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5690670A (en) * 1989-12-21 1997-11-25 Davidson; James A. Stents of enhanced biocompatibility and hemocompatibility
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5919126A (en) * 1997-07-07 1999-07-06 Implant Sciences Corporation Coronary stent with a radioactive, radiopaque coating
US6077298A (en) * 1999-02-20 2000-06-20 Tu; Lily Chen Expandable/retractable stent and methods thereof
US6471721B1 (en) * 1999-12-30 2002-10-29 Advanced Cardiovascular Systems, Inc. Vascular stent having increased radiopacity and method for making same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2451749A (en) * 1946-05-31 1948-10-19 Kreisler Mfg Corp Jacques Bracelet or the like and method of making the same
US4244754A (en) * 1975-07-05 1981-01-13 The Foundation: The Research Institute Of Electric And Magnetic Alloys Process for producing high damping capacity alloy and product
US4891080A (en) * 1988-06-06 1990-01-02 Carpenter Technology Corporation Workable boron-containing stainless steel alloy article, a mechanically worked article and process for making thereof
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US5690670A (en) * 1989-12-21 1997-11-25 Davidson; James A. Stents of enhanced biocompatibility and hemocompatibility
US5449373A (en) * 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5919126A (en) * 1997-07-07 1999-07-06 Implant Sciences Corporation Coronary stent with a radioactive, radiopaque coating
US6077298A (en) * 1999-02-20 2000-06-20 Tu; Lily Chen Expandable/retractable stent and methods thereof
US6471721B1 (en) * 1999-12-30 2002-10-29 Advanced Cardiovascular Systems, Inc. Vascular stent having increased radiopacity and method for making same

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20040204749A1 (en) * 2003-04-11 2004-10-14 Richard Gunderson Stent delivery system with securement and deployment accuracy
US20040267348A1 (en) * 2003-04-11 2004-12-30 Gunderson Richard C. Medical device delivery systems
US7473271B2 (en) 2003-04-11 2009-01-06 Boston Scientific Scimed, Inc. Stent delivery system with securement and deployment accuracy
US9737427B2 (en) 2004-04-09 2017-08-22 Boston Scientific Scimed, Inc. Medical device delivery systems
US9066826B2 (en) 2004-04-09 2015-06-30 Boston Scientific Scimed, Inc. Medical device delivery systems
US20050228478A1 (en) * 2004-04-09 2005-10-13 Heidner Matthew C Medical device delivery systems
WO2005099622A1 (en) 2004-04-09 2005-10-27 Boston Scientific Limited Medical device delivery systems
US7749264B2 (en) 2004-10-08 2010-07-06 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US7344560B2 (en) 2004-10-08 2008-03-18 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20060079953A1 (en) * 2004-10-08 2006-04-13 Gregorich Daniel J Medical devices and methods of making the same
US20060097242A1 (en) * 2004-11-10 2006-05-11 Mitsubishi Denki Kabushiki Kaisha Semiconductor light-emitting device
US20060100696A1 (en) * 2004-11-10 2006-05-11 Atanasoska Ljiljana L Medical devices and methods of making the same
US7727273B2 (en) 2005-01-13 2010-06-01 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US7938854B2 (en) 2005-01-13 2011-05-10 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20100228336A1 (en) * 2005-01-13 2010-09-09 Stinson Jonathan S Medical devices and methods of making the same
US20060153729A1 (en) * 2005-01-13 2006-07-13 Stinson Jonathan S Medical devices and methods of making the same
US20060224231A1 (en) * 2005-03-31 2006-10-05 Gregorich Daniel J Endoprostheses
EP2353554A1 (en) 2005-03-31 2011-08-10 Boston Scientific Limited Stent
US8435280B2 (en) 2005-03-31 2013-05-07 Boston Scientific Scimed, Inc. Flexible stent with variable width elements
US7641983B2 (en) 2005-04-04 2010-01-05 Boston Scientific Scimed, Inc. Medical devices including composites
US20060222844A1 (en) * 2005-04-04 2006-10-05 Stinson Jonathan S Medical devices including composites
US20060229711A1 (en) * 2005-04-05 2006-10-12 Elixir Medical Corporation Degradable implantable medical devices
US10350093B2 (en) 2005-04-05 2019-07-16 Elixir Medical Corporation Degradable implantable medical devices
US20060259126A1 (en) * 2005-05-05 2006-11-16 Jason Lenz Medical devices and methods of making the same
US20060276875A1 (en) * 2005-05-27 2006-12-07 Stinson Jonathan S Medical devices
EP2191794A2 (en) 2005-05-27 2010-06-02 Boston Scientific Limited Medical devices
US20090214373A1 (en) * 2005-05-27 2009-08-27 Boston Scientific Scimed, Inc. Medical Devices
US20060276910A1 (en) * 2005-06-01 2006-12-07 Jan Weber Endoprostheses
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20070114701A1 (en) * 2005-11-18 2007-05-24 Stenzel Eric B Methods and apparatuses for manufacturing medical devices
US7799153B2 (en) 2005-11-18 2010-09-21 Boston Scientific Scimed, Inc. Methods and apparatuses for manufacturing medical devices
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US9011516B2 (en) 2006-06-20 2015-04-21 Boston Scientific Scimed, Inc. Medical devices including composites
US20080161900A1 (en) * 2006-06-20 2008-07-03 Boston Scientific Scimed, Inc. Medical devices including composites
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US20080071355A1 (en) * 2006-09-14 2008-03-20 Boston Scientific Scimed, Inc. Medical Devices with Drug-Eluting Coating
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US7955382B2 (en) 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US20080071344A1 (en) * 2006-09-18 2008-03-20 Boston Scientific Scimed, Inc. Medical device with porous surface
US20080069858A1 (en) * 2006-09-20 2008-03-20 Boston Scientific Scimed, Inc. Medical devices having biodegradable polymeric regions with overlying hard, thin layers
US20100305682A1 (en) * 2006-09-21 2010-12-02 Cleveny Technologies Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
US8769794B2 (en) * 2006-09-21 2014-07-08 Mico Innovations, Llc Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
WO2008063775A3 (en) * 2006-10-13 2009-10-22 Boston Scientific Limited Medical devices including hardened alloys
US7780798B2 (en) 2006-10-13 2010-08-24 Boston Scientific Scimed, Inc. Medical devices including hardened alloys
WO2008063775A2 (en) * 2006-10-13 2008-05-29 Boston Scientific Limited Medical devices including hardened alloys
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
WO2008082698A2 (en) 2006-12-28 2008-07-10 Boston Scientific Limited Medical devices and methods of making the same
US20080160259A1 (en) * 2006-12-28 2008-07-03 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US9034456B2 (en) 2006-12-28 2015-05-19 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US8211162B2 (en) 2007-05-25 2012-07-03 Boston Scientific Scimed, Inc. Connector node for durable stent
US20080294238A1 (en) * 2007-05-25 2008-11-27 Boston Scientific Scimed, Inc. Connector Node for Durable Stent
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US8790392B2 (en) 2007-07-11 2014-07-29 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20110224783A1 (en) * 2007-07-11 2011-09-15 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US20090149942A1 (en) * 2007-07-19 2009-06-11 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118814A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118812A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US20090299468A1 (en) * 2008-05-29 2009-12-03 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090319032A1 (en) * 2008-06-18 2009-12-24 Boston Scientific Scimed, Inc Endoprosthesis coating
US9078777B2 (en) 2008-07-09 2015-07-14 Boston Scientific Scimed, Inc. Stent with non-round cross-section in an unexpanded state
US20100010620A1 (en) * 2008-07-09 2010-01-14 Boston Scientific Scimed, Inc. Stent
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100057188A1 (en) * 2008-08-28 2010-03-04 Boston Scientific Scimed, Inc. Endoprostheses with porous regions and non-polymeric coating
US8114153B2 (en) 2008-09-05 2012-02-14 Boston Scientific Scimed, Inc. Endoprostheses
US20100063584A1 (en) * 2008-09-05 2010-03-11 Boston Scientific Scimed, Inc. Endoprostheses
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100217370A1 (en) * 2009-02-20 2010-08-26 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
WO2010101988A2 (en) 2009-03-04 2010-09-10 Boston Scientific Scimed, Inc. Endoprostheses
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US20110022162A1 (en) * 2009-07-23 2011-01-27 Boston Scientific Scimed, Inc. Endoprostheses
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110238153A1 (en) * 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprostheses
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8895099B2 (en) 2010-03-26 2014-11-25 Boston Scientific Scimed, Inc. Endoprosthesis
US20110238149A1 (en) * 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprosthesis
WO2011119430A1 (en) 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprosthesis
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011126708A1 (en) 2010-04-06 2011-10-13 Boston Scientific Scimed, Inc. Endoprosthesis
US8834560B2 (en) 2010-04-06 2014-09-16 Boston Scientific Scimed, Inc. Endoprosthesis
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US8920490B2 (en) 2010-05-13 2014-12-30 Boston Scientific Scimed, Inc. Endoprostheses
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
WO2012142319A1 (en) 2011-04-13 2012-10-18 Micell Technologies, Inc. Stents having controlled elution
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US11357623B2 (en) 2011-12-13 2022-06-14 Boston Scientific Scimed, Inc. Decalcifying heart valve
US9987130B2 (en) 2011-12-13 2018-06-05 Boston Scientific Scimed, Inc. Decalcifying heart valve
WO2013090145A1 (en) 2011-12-13 2013-06-20 Boston Scientific Scimed, Inc. Decalcifying heart valve
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
CN106148852A (en) * 2015-04-02 2016-11-23 上海微创医疗器械(集团)有限公司 A kind of alloy material and implantable medical devices
CN105821343A (en) * 2016-05-24 2016-08-03 江苏金基特钢有限公司 Production method of special steel
CN116623105A (en) * 2023-07-24 2023-08-22 中科艾尔(北京)科技有限公司 Ultra-high purity 316L stainless steel and preparation method thereof

Similar Documents

Publication Publication Date Title
US20020144757A1 (en) Stainless steel alloy with improved radiopaque characteristics
US8580189B2 (en) Stainless steel alloy having lowered nickel-chrominum toxicity and improved biocompatibility
US7780798B2 (en) Medical devices including hardened alloys
EP1373590B1 (en) Ultra-high-strength precipitation-hardenable stainless steel and elongated strip made therefrom
US6238455B1 (en) High-strength, titanium-bearing, powder metallurgy stainless steel article with enhanced machinability
EP2220261B1 (en) Lean austenitic stainless steel
EP1423548B1 (en) Duplex steel alloy
EP2287346A1 (en) Bainitic steels with boron
EP2455508A1 (en) High strength / corrosion-resistant,.austenitic stainless steel with carbon - nitrogen complex additive, and method for manufacturing same
US11779477B2 (en) Radiopaque intraluminal stents
KR101363674B1 (en) High strength, high toughness steel alloy
US20130103161A1 (en) Iron Based Alloys for Bioabsorbable Stent
US8034197B2 (en) Ultra-high strength stainless steels
EP2676685A1 (en) Stent composed of an iron alloy
JP2002502464A (en) Nickel-free stainless steel for biomedical applications
US6793745B2 (en) Maraging type spring steel
EP1087029A2 (en) Improved steel composition
Herliansyah et al. The effect of annealing temperature on the physical and mechanical properties of stainless steel 316L for stent application
US11702714B2 (en) High fracture toughness, high strength, precipitation hardenable stainless steel
Craig et al. Mechanical properties and microstructure of platinum enhanced radiopaque stainless steel (PERSS) alloys
JP2000239799A (en) Ni-FREE TWO-PHASE STAINLESS STEEL FOR LIVING BODY
EP2634277B1 (en) Co-based alloy for living body and stent
WO2021204811A1 (en) Bioresorbable fe-mn-si-x alloys for medical implants
CN109778079B (en) Stainless steel for medical instruments, manufacturing method, heat treatment method and application
WO2001079576A1 (en) High-strength precipitation-hardenable stainless steel suitable for casting in air

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CRAIG, CHARLES HORACE;RADISCH, HERBERT R., JR.;TROZERA, THOMAS;REEL/FRAME:013080/0722

Effective date: 20020626

AS Assignment

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868

Effective date: 20050101

Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868

Effective date: 20050101

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION